Loading
HKSEHealthcareBiotechnology
Latest quote
HK$8.51
−HK$0.195 · -2.24%
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
Latest quote
HK$8.51
−HK$0.195 · -2.24%
Regular session · HKT · Market data may be delayed.
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
Day range
Current HK$8.51
52-week range
Current HK$8.51
Regular session · HKT · Market data may be delayed.
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
Day range
Current HK$8.51
52-week range
Current HK$8.51
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS9.35M0.00%646.2B USD0.05%$86.04-1.26%
Vanguard FTSE Emerging Markets ETFVWO9.34M0.01%162.3B USD0.06%$59.61-1.23%
iShares Core MSCI Emerging Markets ETFIEMG6.81M0.00%163.33B USD0.09%$80.40-2.62%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS2.55M0.02%13.6B USD0.06%$156.51-1.29%
State Street SPDR Portfolio Emerging Markets ETFSPEM615.09K0.00%17.7B USD0.07%$51.93-1.10%
Vanguard Total World Stock ETFVT614.61K0.00%97.9B USD0.06%$158.73-0.76%
WisdomTree China ex-State-Owned Enterprises FundCXSE351.99K0.08%467.08M USD0.32%$36.3079+0.22%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX249.82K0.04%675.78M USD0.65%$71.74-1.20%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE All-World ex-US Small-Cap ETFVSSState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard Total World Stock ETFVTWisdomTree China ex-State-Owned Enterprises FundCXSEState Street SPDR S&P Emerging Markets Small Cap ETFEWXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
